Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Small-cap volatility can threaten predictable retirement income. This note covers swing risk and how to cushion portfolios with prudent diversification.
23,862 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
NVIDIA’s shares hover near $198 as investors weigh whether the AI leader’s growth justifies a premium. The stock now ...
As JJSF prepares for its 2026 earnings call, investors will scrutinize margins, pricing power, and capital allocation...
Record exports could drive a U.S. fuel crunch as travelers hit the roads this summer, with diesel stocks near a 20-ye...
Star Group's Q2 2026 results shed light on the company's path to profitability and growth. This article breaks down t...
IREN leaps on a landmark NVIDIA AI Cloud contract and a parallel equity option, signaling a strategic pivot from cryp...
A leading economist argues that recessions aren’t predictable cycles after studying four centuries of data, urging ho...
Apple signals a strategic pivot, moving its flagship away from the iPhone toward ambient computing with Vision Pro an...
The Senate Banking Committee unveiled a sweeping 309-page crypto bill early Tuesday, aiming to overhaul market struct...
Ted Turner's open-loop model created the modern attention economy. This report analyzes its lasting impact on persona...
Solana is trading near $97 as traders weigh a potential move above $100 this month. Analysts point to ETF demand and ...
Micron Technology rides a rapid AI-fueled rally into May, fueling debate among investors about whether to sell or hol...